Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

Détails

ID Serval
serval:BIB_844DA409294E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Périodique
Expert Opinion On Drug Metabolism and Toxicology
Auteur(s)
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C.
ISSN
1744-7607 (Electronic)
ISSN-L
1742-5255
Statut éditorial
Publié
Date de publication
2011
Volume
7
Numéro
5
Pages
609-622
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
INTRODUCTION: Besides therapeutic effectiveness, drug tolerability is a key issue for treatments that must be taken indefinitely. Given the high prevalence of toxicity in HIV therapy, the factors implicated in drug-induced morbidities should be identified in order to improve the safety, tolerability and adherence to the treatments. Current approaches have focused almost exclusively on parent drug concentrations; whereas recent evidence suggests that drug metabolites resulting from complex genetic and environmental influences can also contribute to treatment outcome. Pharmacogenetic variations have shown to play a relevant role in the variability observed in antiretroviral drug exposure, clinical response and sometimes toxicity. The integration of pharmacokinetic, pharmacogenetic and metabolic determinants will more probably address current therapeutic needs in patients.
AREAS COVERED: This review offers a concise description of three classes of antiretroviral drugs. The review looks at the metabolic profile of these drugs and gives a comprehensive summary of the existing literature on the influence of pharmacogenetics on their pharmacokinetics and metabolic pathways, and the associated drug or metabolite toxicity.
EXPERT OPINION: Due to the high prevalence of toxicity and the related risk of low adherence to the treatments, association of kinetic, genetic and metabolic markers predictive of therapeutic or toxicity outcomes could represent a more complete approach for optimizing antiretroviral therapy.
Mots-clé
Animals, Anti-HIV Agents/adverse effects, Anti-HIV Agents/pharmacokinetics, Diethylpropion, HIV Infections/drug therapy, Humans, Pharmacogenetics
Pubmed
Web of science
Création de la notice
13/05/2011 9:24
Dernière modification de la notice
20/08/2019 14:43
Données d'usage